Document is current
Any future updates will be listed below
-
Authors
Vaghjiani, Vijesh G.
Cochrane, Catherine R.
Jayasekara, W. Samantha N.
Chong, Wai Chin
Szczepny, Anette
Kumar, Beena
Martelotto, Luciano G.
McCaw, Andrew
Carey, Kirstyn
Kansara, Maya
Thomas, David M. http://orcid.org/0000-0002-2527-5428
Walkley, Carl http://orcid.org/0000-0002-4784-9031
Mudge, Stuart
Gough, Daniel J. http://orcid.org/0000-0001-6479-1735
Downie, Peter A.
Peacock, Craig D. http://orcid.org/0000-0001-8139-8628
Matsui, William
Watkins, D. Neil
Cain, Jason E. http://orcid.org/0000-0003-3987-5894
-
Funding
Funding for this research was provided by:
Victorian Cancer Agency (ECSG11_09, MCRF17014, MCRF19033)
Cancer Council NSW (RG15-07, RG15-07)
Bailey’s Day
Science and Industry Endowment Fund
Monash University
Petre Foundation
- License Information
-
More Information
Article History
Received: 22 February 2021
Revised: 26 September 2023
Accepted: 4 October 2023
First Online: 16 October 2023
Competing interests
: VGV, CRC, SM, DNW and JEC are coinventors on a patent application relating to aspects of this work (US Patent 63/07255). DNW is a coinventor on a patent (US Patent 60/512,651) relating to aspects of this work and is a financial beneficiary of a licencing agreement related to the use of SMO antagonists in small cell lung cancer. DNW and JEC were paid consultants for Mayne Pharma. VGV is the recipient of a Science and Industry Endowment Fund STEM+ Business Fellowship in partnership with Mayne Pharma. SM was an employee of Mayne Pharma International Pty Ltd.
